title: Preemptive (neoadjuvant) chemotherapy: can analysis of eligibility criteria, prognostic factors, and tumor staging from different trials provide valid or useful comparisons?
authors.affiliation: Urological Cancer Research Unit, Royal Prince Alfred Hospital, Sydney, Australia.
authors.forename: D
authors.initials: D
authors.lastname: Raghavan
authors.forename: M
authors.initials: M
authors.lastname: Wallace
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation / Q000379:methods; D006801:Humans; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology